BioSpace News Archive

Rgenta Therapeutics announced the presentation of preclinical data at ASCO 2024 from its lead program, RGT-61159, which is being developed for the potential treatment of adenoid cystic carcinoma, colorectal cancer and other solid tumors as well as acute myeloid leukemia.

Valneva SE announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending authorization of Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.

AstraZeneca is pleased to announce that Truqap™ in combination with fulvestrant is now available in Canada for the treatment of adult female patients with hormone receptor -positive, human epidermal growth factor receptor 2 -negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1 or PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications, launch a new assay for quantifying pharmacodynamic markers of radioligand therapies in tumors.

Houston-area clinical research organization Hope Biosciences Research Foundation shares topline results of a randomized, placebo-controlled Phase II study to evaluate Hope Biosciences’ adipose‑derived allogeneic mesenchymal stem cell therapy for patients with Post‑COVID‑19 syndrome.

Johnson & Johnson announced new data from the Phase 3 MARIPOSA study demonstrating the benefit of first-line treatment with RYBREVANT® in combination with lazertinib in patients with high-risk disease or clinical features, which occur in nearly 85 percent of patients with non-small cell lung cancer with epidermal growth factor receptor mutations.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 9 individuals hired by Sarepta in May 2024.

Vivacelle Bio announced that Cuthbert Simpkins MD, FACS, President and Chief Innovation Officer, has been invited by the National Institutes of Health to present data highlighting the company’s late-stage clinical programs at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024.

Immunocore reports updated Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

China Jo-Jo Drugstores, Inc., a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, announced that Ms. Pingfan Wu has resigned from her position as a member of the board of directors due to personal reasons, effective on May 31, 2024.